| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/25/2011 | EP2323637A1 Treatment of fibrotic eye disorders |
| 05/25/2011 | EP2323634A1 Ropinirole composition |
| 05/25/2011 | EP2323633A2 Stable pharmaceutical composition for optimized delivery of an hiv attachment inhibitor |
| 05/25/2011 | EP2323632A1 Retard tablets containing quetiapine |
| 05/25/2011 | EP2323628A2 Carrier nanoparticles and related compositions, methods and systems |
| 05/25/2011 | EP2323627A1 Novel rapid-effect pharmaceutical forms and uses of resulting pharmaceutical compositions |
| 05/25/2011 | EP2323624A2 Modulation of toll-like receptor 8 expression by antisense oligonucleotides |
| 05/25/2011 | EP2323612A1 Series of skin-whitening (lightening) compounds |
| 05/25/2011 | EP2323605A1 Transdermal delivery of oligosaccharides |
| 05/25/2011 | EP2323589A1 Coating with antimicrobial agents |
| 05/25/2011 | EP2323485A1 Anti-allergen combinations of calcium and lanthanum salts |
| 05/25/2011 | EP2323482A1 Substituted dihydroisoquinolinone and isoquinolinedione derivatives as calcium channel blockers |
| 05/25/2011 | EP2252284B1 Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability |
| 05/25/2011 | EP2212297B1 Inhibitors of protein kinases |
| 05/25/2011 | EP2197860B1 New compounds as adenosine a1 receptor antagonists |
| 05/25/2011 | EP2158207B1 Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase |
| 05/25/2011 | EP2125748B1 Acylaminopyrazoles as fgfr inhibitors |
| 05/25/2011 | EP2114406B1 Thioxanthene derivates as sole anti-infective agents for use in the treatment of infectious diseases |
| 05/25/2011 | EP2056818B1 Compositions and methods for neuroprotection |
| 05/25/2011 | EP2056805B1 Use of 2, 5-dihydroxybenzene derivatives for the treatment of tissue reactive diseases |
| 05/25/2011 | EP2035436B1 Fused thiazole derivatives as kinase inhibitors |
| 05/25/2011 | EP2021335B1 Heterocyclic compounds as inhibitors of c-fms kinase |
| 05/25/2011 | EP1951672B1 Potassium channel inhibitors |
| 05/25/2011 | EP1945270B1 Compositions and methods for inhibiting expression of factor v leiden mutant gene |
| 05/25/2011 | EP1919304B1 Compositions and methods for improving functional vascular integrity, cellular survival and reducing apoptosis after an ischemic episode in the brain |
| 05/25/2011 | EP1894576B1 Novel triglyceride reducing agent |
| 05/25/2011 | EP1868994B1 Sulfonylpyrroles as histone deacetylase inhibitors |
| 05/25/2011 | EP1863787B1 Hydogrenated benzo[c]thiophene derivatives as immunomodulators |
| 05/25/2011 | EP1827379B8 Formulations containing alkylphosphocholines using novel negative charge carriers |
| 05/25/2011 | EP1781294B1 Composition for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
| 05/25/2011 | EP1755620B1 Sulphated depolymerised exopolysaccharide derivatives, their preparation and uses |
| 05/25/2011 | EP1534296B1 Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| 05/25/2011 | EP1482912B1 Naltrexone hydrochloride compositions |
| 05/25/2011 | EP1470102B1 Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (ptps) |
| 05/25/2011 | EP1439847B1 Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract |
| 05/25/2011 | EP1425035B1 Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 05/25/2011 | EP1374902B1 Anti-AILIM antibodies for the treatment of Crohn's disease |
| 05/25/2011 | EP1372674B1 Facially amphiphilic polymers as anti-infective agents |
| 05/25/2011 | EP1349562B1 Inhibiting gs-fdh to modulate no bioactivity |
| 05/25/2011 | EP1335726B1 Modified prodrug forms of ap |
| 05/25/2011 | EP1317454B1 Caspase inhibitors and uses thereof |
| 05/25/2011 | EP1294361B1 Compositions and methods to improve the oral absorption of antimicrobial agents |
| 05/25/2011 | EP0959896B1 Method of producing secreted truncated variants of human thyrotropin receptor |
| 05/25/2011 | EP0947584B1 Loxoprofen-containing preparation for external use |
| 05/25/2011 | CN1980674B Phthalazine derivatives as parp inhibitors |
| 05/25/2011 | CN1976692B Methods and compositions for treating ophthalmic conditions with retinyl derivates |
| 05/25/2011 | CN1976690B Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis |
| 05/25/2011 | CN1942177B Bazedoxifene acetate solid dispersion formulations |
| 05/25/2011 | CN1913872B Pre-metered dry powder inhaler for moisture-sensitive medicaments |
| 05/25/2011 | CN1882698B Hypoxia-inducible protein 2 (HIG2)serving as a novel therapeutic potential target of renal cell carcinoma (RCC) |
| 05/25/2011 | CN1849330B Specific glucocorticosteroid compound having anti-inflammatory activity |
| 05/25/2011 | CN1816538B Preventive or therapeutic composition for viral infectious disease |
| 05/25/2011 | CN1785180B Method for detecting compound bismuth potassium citrate metronidazole |
| 05/25/2011 | CN1771231B Calcium receptor modulating compound and use thereof |
| 05/25/2011 | CN1665764B An hydroxytyrosol-rich composition from olive vegetation water and method of use thereof |
| 05/25/2011 | CN1578663B Inhibitors of histone deacetylase |
| 05/25/2011 | CN102076865A Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| 05/25/2011 | CN102076854A Rna antagonist compounds for inhibition of expression of mitochondrial glycerol-3-phosphate acyltransferase 1 (mtgpat1) |
| 05/25/2011 | CN102076853A Enhancement of drug therapy by mirna |
| 05/25/2011 | CN102076852A Modulation of factor 7 expression |
| 05/25/2011 | CN102076704A Synthesis of timosaponin BII |
| 05/25/2011 | CN102076699A Hydrogensulfate salt of 2-acetoxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and its preparation |
| 05/25/2011 | CN102076698A 2h- pyrimido [2, 1-b] quinaz0lin-2-0ne derivatives and their use as platelet anti-aggregative agents |
| 05/25/2011 | CN102076697A Substituted quinazolines and their uses for myeoloprolific and thrombotic diseases |
| 05/25/2011 | CN102076696A Substituted quinazolines |
| 05/25/2011 | CN102076695A Imidazoquinazoline derivatives as anagrelide analogues for the treatment of myeloprolific diseases and thrombotic diseases |
| 05/25/2011 | CN102076694A 5, 6, 7, 8-tetrahydro-imidazo[1, 5-a]pyrazine compounds |
| 05/25/2011 | CN102076693A Substituted tricyclic derivatives against neurodegenerative diseases |
| 05/25/2011 | CN102076692A Triazolo [4, 5-D] pyramidine derivatives and their use as purine receptor antagonists |
| 05/25/2011 | CN102076691A Protein kinase inhibitors |
| 05/25/2011 | CN102076690A Protein kinase inhibitors |
| 05/25/2011 | CN102076689A Pyrazolo-quinazolines |
| 05/25/2011 | CN102076688A Purine derivatives further comprising a mercapto-acylamino group as neutral endopeptidase inhibitors |
| 05/25/2011 | CN102076687A Substituted quinazolines as blood platelet lowering agents |
| 05/25/2011 | CN102076686A Diketopiperidine derivatives as HIV attachment inhibitors |
| 05/25/2011 | CN102076685A Substituted quinazolines |
| 05/25/2011 | CN102076684A Substituted pyrimidin-4-one derivatives |
| 05/25/2011 | CN102076683A Substituted pyrimido [2, 1-a] isoquinolin-4-one derivatives |
| 05/25/2011 | CN102076682A Five-membered ring compound |
| 05/25/2011 | CN102076681A Substituted gamma lactams as therapeutic agents |
| 05/25/2011 | CN102076680A Benzoimidazoles as prolyl hydroxylase inhibitors |
| 05/25/2011 | CN102076679A Novel tetramethyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 05/25/2011 | CN102076678A Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors |
| 05/25/2011 | CN102076672A Novel five-membered ring compound |
| 05/25/2011 | CN102076671A Triazole derivative or salt thereof |
| 05/25/2011 | CN102076670A Compounds and methods for modulating g protein-coupled receptors |
| 05/25/2011 | CN102076669A Substituted n-oxide pyrazine derivatives |
| 05/25/2011 | CN102076668A Substituted quinazolines |
| 05/25/2011 | CN102076667A Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives |
| 05/25/2011 | CN102076666A Aminopyridine derivatives |
| 05/25/2011 | CN102076665A Organic compounds |
| 05/25/2011 | CN102076664A A process for producing lercanidipine HCL form v |
| 05/25/2011 | CN102076663A Piperidinyl derivative as modulator of chemokine receptor activity |
| 05/25/2011 | CN102076662A Alpha-mercapto-amides |
| 05/25/2011 | CN102076661A Antagonists of prostaglandin d2 receptors |
| 05/25/2011 | CN102076660A Sulfonamide compound or salt thereof |
| 05/25/2011 | CN102076654A Benzocycloheptane and benzoxepine derivatives |
| 05/25/2011 | CN102076650A Carboxylic acid compound |
| 05/25/2011 | CN102076362A Nicotine lozenge compositions |
| 05/25/2011 | CN102076352A Fgf-9 and its use relating to blood vessels |